We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Reply to: Reconciling differences in impact of molecular subtyping on response to cisplatin-based chemotherapy.
- Authors
Taber, Ann; Christensen, Emil; Lamy, Philippe; Agerbæk, Mads; Jensen, Jørgen Bjerggaard; Dyrskjøt, Lars
- Abstract
Finally, in our study, we observed lower chemotherapy response rates for patients with a Ba/Sq gene expression subtype and for patients with low genomic instability. In our study, we included analysis of localized tumors from patients that received NAC and from patients that received first-line chemotherapy for metastatic disease. The response was defined by noninvasive pathological downstaging for patients treated with NAC and complete or partial response (RECIST 1.1) assessed by radiological imaging for patients treated with first-line chemotherapy. Both response measures evaluate tumor shrinkage following chemotherapy and therefore give a direct indication of response to cisplatin-based chemotherapy despite large differences in survival for the two patient cohorts.
- Subjects
CANCER chemotherapy; GENETIC mutation; CELL-free DNA; OVERALL survival; CANCER invasiveness
- Publication
Nature Communications, 2021, Vol 12, Issue 1, p1
- ISSN
2041-1723
- Publication type
Letter
- DOI
10.1038/s41467-021-24839-6